Keeps Biopharma (256940) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Keeps Biopharma (256940) reported revenue of 170.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025170.1 billion KRW1.6 billion KRW-10.4 billion KRW[source]
2024127.6 billion KRW6.2 billion KRW1.6 billion KRW[source]
202392.1 billion KRW3.1 billion KRW3.5 billion KRW[source]
202214.6 billion KRW-8.6 billion KRW-12.0 billion KRW[source]
20214.3 billion KRW-12.3 billion KRW-16.2 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025179.2 billion KRW100.2 billion KRW79.0 billion KRW[source]
2024105.8 billion KRW44.4 billion KRW61.4 billion KRW[source]
202391.8 billion KRW41.2 billion KRW50.5 billion KRW[source]
202291.1 billion KRW32.3 billion KRW58.8 billion KRW[source]
202199.3 billion KRW31.7 billion KRW67.5 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice